Inhibikase Therapeutics Inc (NAS:IKT)

$ 2.92 0.19 (6.96%) Market Cap: 196.20 Mil Enterprise Value: 193.10 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 39/100

Q2 2024 Inhibikase Therapeutics Inc Earnings Call Transcript
Aug 15, 2024

$1.23 (-5.38%)

Earnings
Q1 2024 Inhibikase Therapeutics Inc Earnings Call Transcript
May 16, 2024

$1.76 (-11.56%)

Earnings
Q4 2023 Inhibikase Therapeutics Inc Earnings Call Transcript
Mar 28, 2024

$2.16 (-6.09%)

Earnings
Q2 2023 Inhibikase Therapeutics Inc Earnings Call Transcript
Aug 15, 2023

$2.34 (-6.02%)

Earnings
Inhibikase Therapeutics Inc at LD Micro Invitational Conference Transcript
Jun 06, 2023
Q1 2023 Inhibikase Therapeutics Inc Earnings Call Transcript
May 16, 2023

$3.91 (-1.33%)

Earnings
Q4 2022 Inhibikase Therapeutics Inc Earnings Call Transcript
Apr 03, 2023

$3.71 (-6.04%)

Earnings
Inhibikase Therapeutics Inc R&D Event Transcript
Mar 22, 2023
Q1 2022 Inhibikase Therapeutics Inc Earnings Call Transcript
May 17, 2022

$4.26 (+1.63%)

Earnings
Inhibikase Therapeutics Inc at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript
Apr 28, 2022
Inhibikase Therapeutics Inc at LD Micro Microcap Invitational Conference (Virtual) Transcript
Jun 10, 2021
Inhibikase Therapeutics Inc at Sachs Associates Neuroscience Innovation Forum (Virtual) Transcript
Apr 28, 2021
Inhibikase Therapeutics Inc at Truist Securities Life Sciences Summit (April Series) Transcript
Apr 13, 2021
Inhibikase Therapeutics Inc at ASENT Neurotherapeutics Conference (Virtual) Transcript
Feb 25, 2021

Inhibikase Therapeutics Inc at LD Micro Microcap Invitational Conference (Virtual) Transcript

Jun 10, 2021 / 03:30PM GMT

Release Date Price: $36.96 (+8.07%)

Transcript

John Peyton

Sequire - Analyst

Hi, my name is John Peyton, Business Development at Sequire shareholder insight and acquisition. And I'm here to present Milton Werner, CEO at Inhibikase Therapeutics. In many cases, a clinical-stage pharmaceutical company, developing therapeutics for Parkinson's disease and related central nervous system disorders that arise inside and outside of the brain. The company was founded in 2008 and is headquartered in Atlanta, Georgia. Milton, take it away.

Milton Werner

Inhibikase Therapeautics, Inc. - President & CEO

Well, thank you very much for inviting Inhibikase Therapeutics to present at the LD Micro Conference. Inhibikase is a small-molecule kinase inhibitor focused company recently listed on the Nasdaq under the symbol IKT. And what I will try to tell you about today is our work in the clinic whose intent is to develop therapies that can reverse functional loss in Parkinson's disease and related indications.

Just because we're a public company, I'm going to be making a number of forward-looking statements. And

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.